Benefits
LDL cholesterol reduction
Multiple Italian RCTs (Mollace 2011, Toth 2016, others) demonstrate standardized BPF at 1,000 mg/day reduces LDL cholesterol by 24-36% — approaching statin-level efficacy for a natural supplement. The brutieridin and melitidin content provides direct HMG-CoA reductase inhibition similar to statin drugs.
Triglyceride and VLDL reduction
BPF consistently reduces triglycerides by 30-39% across clinical trials — one of the more potent natural triglyceride-lowering ingredients available. VLDL cholesterol is also significantly reduced, addressing comprehensive lipid management.
HDL cholesterol elevation
Unlike most cholesterol-lowering interventions that reduce LDL without raising HDL, BPF consistently increases HDL cholesterol by 15-40% in clinical trials — a comprehensive lipid panel improvement uncommon with single interventions.
Blood glucose and insulin resistance improvement
BPF significantly reduces fasting blood glucose, postprandial glucose, HbA1c, and insulin resistance in metabolic syndrome and prediabetic populations. AMPK activation improves skeletal muscle glucose uptake and reduces hepatic gluconeogenesis.
Statin adjunct (reduces statin doses)
Clinical trials (Gliozzi 2013) show BPF combined with low-dose rosuvastatin (10 mg) is equivalent or superior to higher-dose rosuvastatin (20 mg) alone — suggesting BPF allows lower statin dosing with potentially fewer side effects. Important practical implication for patients with statin intolerance.
NAFLD / hepatic steatosis support
BPF reduces liver enzymes (ALT, AST, GGT) and hepatic steatosis markers in non-alcoholic fatty liver disease patients. Mechanism: AMPK activation, reduced de novo lipogenesis. Supports use for NAFLD-metabolic syndrome cluster.
Distinct from bergamot essential oil
Important consumer education: bergamot ESSENTIAL OIL (used in Earl Grey tea flavoring, perfumes) is the photosensitizing aromatic oil from peel — DIFFERENT from the polyphenolic fraction (BPF) used in supplements. BPF does NOT cause photosensitivity; only the essential oil does.
Mechanism of action
HMG-CoA reductase inhibition (statin-like mechanism)
Brutieridin and melitidin — polyphenols unique to Citrus bergamia — contain a hydroxymethylglutaric acid moiety that directly inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Same target as statins and red yeast rice.
AMPK activation
BPF activates AMP-activated protein kinase (AMPK) via the LKB1 pathway, stimulating fatty acid oxidation, increasing LDL receptor expression, and reducing hepatic gluconeogenesis. Master metabolic regulator effect.
PCSK9 inhibition and LDL receptor upregulation
Bergamot flavonoids inhibit PCSK9 (proprotein convertase subtilisin/kexin type 9) — the same target as the newest generation of injectable cholesterol medications (alirocumab, evolocumab). Increases LDL receptor density on hepatocytes.
Antioxidant activity
BPF flavonoids (neoeriocitrin, naringin, neohesperidin) are potent antioxidants — protect LDL particles from oxidation, reduce inflammatory markers. Complements the cholesterol-lowering effects with vascular protection.
Gut microbiome effects (emerging)
Emerging research: BPF polyphenols modulate gut microbiome composition, increase short-chain fatty acid producers — additional metabolic benefit pathway beyond direct enzyme inhibition.
Clinical trials
Foundational clinical trial establishing BPF as effective cholesterol agent.
Clinical population described in trial publication.
Foundational clinical trial establishing BPF as effective cholesterol agent. BPF dose-dependently reduced LDL cholesterol (by 24-36% in 1,000 mg group), triglycerides (30-39%), and increased HDL (22-40%) vs placebo. Fasting plasma glucose reduced 15-22%. The 1,000 mg dose showed strongest effects.
Combined low-dose rosuvastatin + bergamot produced LDL reductions comparable to high-dose rosuvastatin alone (-52% combination vs -57% high-dose statin), with greater reductions in oxidative stress markers.
Clinical population described in trial publication.
Combined low-dose rosuvastatin + bergamot produced LDL reductions comparable to high-dose rosuvastatin alone (-52% combination vs -57% high-dose statin), with greater reductions in oxidative stress markers. Demonstrates synergy and dose-reduction potential.
Bergamot extract significantly reduced hepatic steatosis on ultrasound, decreased ALT and AST, and improved lipid profile and fasting glucose vs placebo.
Clinical population described in trial publication.
Bergamot extract significantly reduced hepatic steatosis on ultrasound, decreased ALT and AST, and improved lipid profile and fasting glucose vs placebo. Supports bergamot for the NAFLD-metabolic syndrome cluster, addressing a common clinical pattern.